Paper39459028
Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications.
Debnath SK and 4 others. Pharmaceuticals (Basel), 2024. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications. Papers, record 39459028. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39459028
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References79
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26848553 | Perfluorocarbon-Loaded Hollow Bi2Se3 Nanoparticles for Timely Supply of Oxygen under Near-Infrared Light to Enhance the Radiotherapy of Cancer. | Adv Mater | 2016 | https://conductscience.org/library/papers/26848553 | PubMed |
| 2 | 34191525 | Reversing Hypoxia with PLGA-Encapsulated Manganese Dioxide Nanoparticles Improves Natural Killer Cell Response to Tumor Spheroids. | Mol Pharm | 2021 | https://conductscience.org/library/papers/34191525 | PubMed |
| 3 | 25581937 | Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma. | Neurosurg Focus | 2014 | https://conductscience.org/library/papers/25581937 | PubMed |
| 4 | 27768978 | TaOx decorated perfluorocarbon nanodroplets as oxygen reservoirs to overcome tumor hypoxia and enhance cancer radiotherapy. | Biomaterials | 2017 | https://conductscience.org/library/papers/27768978 | PubMed |
| 5 | 32316260 | Hypoxia-Driven Immune Escape in the Tumor Microenvironment. | Cells | 2020 | https://conductscience.org/library/papers/32316260 | PubMed |
| 6 | 33802292 | Advanced Imaging Techniques for Radiotherapy Planning of Gliomas. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33802292 | PubMed |
| 7 | 36545470 | Anticarcinogenic potentials of tea catechins. | Front Nutr | 2022 | https://conductscience.org/library/papers/36545470 | PubMed |
| 8 | 34439338 | Glucose Transporters as a Target for Anticancer Therapy. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34439338 | PubMed |
| 9 | 34525344 | Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. | Cell Chem Biol | 2022 | https://conductscience.org/library/papers/34525344 | PubMed |
| 10 | 34628029 | Hypoxia signaling: Challenges and opportunities for cancer therapy. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/34628029 | PubMed |
| 11 | 34476218 | Vascular Normalization: A New Window Opened for Cancer Therapies. | Front Oncol | 2021 | https://conductscience.org/library/papers/34476218 | PubMed |
| 12 | 33106581 | Hypoxia and its therapeutic possibilities in paediatric cancers. | Br J Cancer | 2021 | https://conductscience.org/library/papers/33106581 | PubMed |
| 13 | 38346140 | Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy? | Crit Rev Microbiol | 2024 | https://conductscience.org/library/papers/38346140 | PubMed |
| 14 | 33059825 | Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. | Semin Nucl Med | 2020 | https://conductscience.org/library/papers/33059825 | PubMed |
| 15 | 32974385 | Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. | Front Mol Biosci | 2020 | https://conductscience.org/library/papers/32974385 | PubMed |
| 16 | 36968288 | Tumor microenvironment in glioblastoma: Current and emerging concepts. | Neurooncol Adv | 2023 | https://conductscience.org/library/papers/36968288 | PubMed |
| 17 | 33401572 | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33401572 | PubMed |
| 18 | 34665844 | PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair. | PLoS One | 2021 | https://conductscience.org/library/papers/34665844 | PubMed |
| 19 | 33173809 | Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. | Adv Ther (Weinh) | 2021 | https://conductscience.org/library/papers/33173809 | PubMed |
| 20 | 30837280 | Artificial Oxygen Carriers-Past, Present, and Future-a Review of the Most Innovative and Clinically Relevant Concepts. | J Pharmacol Exp Ther | 2019 | https://conductscience.org/library/papers/30837280 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42930087 | Hypoxia-Responsive Fluorescent Prodrugs: Self-Reporting Drug Delivery or Activation in Living Systems. | Biosensors (Basel) | 2026 | https://conductscience.org/library/papers/42930087 | PubMed |
| 42841004 | Multifunctional Cu2-xSe nanomaterials for cancer theranostics: recent advances, therapeutic mechanisms, and translational challenges. | Front Chem | 2026 | https://conductscience.org/library/papers/42841004 | PubMed |
| 42793219 | Hypoxia-Targeting Strategies in Radiotherapy and Nitroimidazole-Based Radiosensitizers: A Narrative Review and Translational Perspectives. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42793219 | PubMed |
| 42455224 | Artificial Blood and Stem Cell-Derived Oxygen Therapeutics in Oncology: Emerging Strategies for Overcoming Tumor Hypoxia. | Stem Cell Rev Rep | 2026 | https://conductscience.org/library/papers/42455224 | PubMed |
| 42440727 | Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics. | Front Oncol | 2026 | https://conductscience.org/library/papers/42440727 | PubMed |
| 42274568 | Sulforaphane Enhances Cytotoxic Effects of Non-Thermal Plasma and Tirapazamine Combination Therapy in Pancreatic Adenocarcinoma Cells. | Cells | 2026 | https://conductscience.org/library/papers/42274568 | PubMed |
| 41723762 | Nervous and immune system crosstalk shapes cancer progression and treatment response. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41723762 | PubMed |
| 41677522 | Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy. | Nanomaterials (Basel) | 2026 | https://conductscience.org/library/papers/41677522 | PubMed |
| 41625776 | Recent advances in lipid nanoparticles for cancer vaccine delivery: Challenges and future perspectives. | Int J Pharm X | 2026 | https://conductscience.org/library/papers/41625776 | PubMed |
| 41521160 | Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. | Cancer Med | 2026 | https://conductscience.org/library/papers/41521160 | PubMed |
| 41516303 | Lanthanide Nanotheranostics in Radiotherapy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516303 | PubMed |
| 41516128 | Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516128 | PubMed |
| 41514600 | Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514600 | PubMed |
| 41424453 | Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41424453 | PubMed |
| 41409250 | Deciphering molecular pathways driving cancer invasion and metastasis: advances and therapeutic prospects. | Front Oncol | 2025 | https://conductscience.org/library/papers/41409250 | PubMed |
| 41089309 | Emerging strategies in radiation therapy: promises and challenges of spatial fractionation, ultra-high dose rates, and nanoparticles. | J Phys D Appl Phys | 2025 | https://conductscience.org/library/papers/41089309 | PubMed |
| 40963621 | Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease - a link between cancer and autoimmunity. | Front Immunol | 2025 | https://conductscience.org/library/papers/40963621 | PubMed |
| 40943387 | Computational Discovery of Selective Carbonic Anhydrase IX (CA IX) Inhibitors via Pharmacophore Modeling and Molecular Simulations for Cancer Therapy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943387 | PubMed |
| 40867257 | Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40867257 | PubMed |
| 40486631 | Oxygen gradients in tumor tissues implications for breast cancer metastasis - a narrative review. | Ann Med Surg (Lond) | 2025 | https://conductscience.org/library/papers/40486631 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39459028
GET https://conductscience.org/api/papers/v1/39459028/references?page=2